← FDA DRUG APPROVALS

FDA ANDA · ANDA075752

LISINOPRIL

Sponsor: HERITAGE PHARMA

APPLICATION
ANDA075752
TYPE
ANDA
ORIGINAL APPROVAL
2002-07-01
LATEST ACTION
2024-05-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LISINOPRILDiscontinued
LISINOPRIL 30MG · TABLET · ORAL
LISINOPRILDiscontinued
LISINOPRIL 10MG · TABLET · ORAL
LISINOPRILDiscontinued
LISINOPRIL 2.5MG · TABLET · ORAL
LISINOPRILDiscontinued
LISINOPRIL 40MG · TABLET · ORAL
LISINOPRILDiscontinued
LISINOPRIL 20MG · TABLET · ORAL
LISINOPRILDiscontinued
LISINOPRIL 5MG · TABLET · ORAL

Approval history

2024-05-30Labeling · Supplement 41 · standardAP
2016-03-24Labeling · Supplement 40 · standardAP
2015-04-24Labeling · Supplement 38 · standardAP
2015-04-24Labeling · Supplement 36 · standardAP
2015-04-24Labeling · Supplement 39 · standardAP
2015-04-24Labeling · Supplement 37 · standardAP
2013-08-01Labeling · Supplement 28AP
2013-08-01Labeling · Supplement 32 · standardAP
2013-08-01Labeling · Supplement 30 · standardAP
2013-08-01Labeling · Supplement 35 · standardAP
2010-12-09Manufacturing (CMC) · Supplement 23AP
2010-02-22Labeling · Supplement 22AP
2008-04-29Labeling · Supplement 13AP
2007-11-05Labeling · Supplement 12AP
2006-02-17Labeling · Supplement 7AP
2005-06-29Labeling · Supplement 5AP
2002-07-01OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →